Crossmark

Third-generation versus first-generation EGFR tyrosine kinase inhibitors in Asian patients with advanced EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1007/s12672-025-03767-7

Published Online: 2025-10-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Manzhen

Ding, Wei

Wan, Linlin

Zhang, Wenxiong
License Information

Text and Data Mining valid from 2025-10-21

Version of Record valid from 2025-10-21
More Information

Article History

Received: 30 July 2025

Accepted: 29 September 2025

First Online: 21 October 2025

Declarations

:

: Due to the nature of this study no ethical approval was required.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below